• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
November 7, 2018 06:54 AM EST
R&D

Foamix claims goal-win­ning suc­cess in twin piv­otal stud­ies for rosacea — shares spike

John Carroll

Editor & Founder

The roller coast­er ride that Foamix Phar­ma­ceu­ti­cals has tak­en in­vestors on is on an up­swing track this morn­ing. The biotech re­port­ed that its top­i­cal for­mu­la­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Will An­tag's bet on GIP block­ade in obe­si­ty pay off? July 11, 2025
  • Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties July 11, 2025
  • Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body July 10, 2025
TRENDING NOW

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Take­da’s first-in-class nar­colep­sy drug suc­ceeds in two reg­is­tra­tional stud­ies

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times